Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

103.60USD
25 May 2018
Change (% chg)

$-1.13 (-1.08%)
Prev Close
$104.73
Open
$104.82
Day's High
$107.06
Day's Low
$103.58
Volume
76,897
Avg. Vol
176,037
52-wk High
$152.55
52-wk Low
$100.64

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $4,511.16
Shares Outstanding(Mil.): 43.54
Dividend: --
Yield (%): --

Financials

  UTHR.OQ Industry Sector
P/E (TTM): 8.20 238.69 33.30
EPS (TTM): 12.63 -- --
ROI: 22.95 -7.54 13.04
ROE: 24.85 -10.33 14.90

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

Apr 30 2018

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

Apr 27 2018

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage:

Mar 30 2018

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Feb 21 2018

BRIEF-United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

* UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM

Feb 15 2018

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* ‍CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION​

Feb 15 2018

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

Jan 03 2018

United Therapeutics to pay $210 million to resolve U.S. kickback probe

BOSTON United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

Dec 20 2017

UPDATE 2-United Therapeutics to pay $210 mln to resolve U.S. kickback probe

BOSTON, Dec 20 United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

Dec 20 2017

Earnings vs. Estimates